Media Articles Related to Aerobid (Flunisolide Inhalation)
Study Confirms Higher CVD Risk in Late-Onset Asthma
Source: Medscape Allergy & Clinical Immunology Headlines [2016.08.27]
Although early- and late-onset asthma are often lumped together, the risk for CVD events follows distinctly different paths in these patients, the authors caution.
Heartwire from Medscape
PTSD in 9/11 Workers Linked to Higher Asthma Risk (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2016.08.27]
(MedPage Today) -- Causal mechanism related to stress appears likely, investigators say
Biologic Therapy in the Management of Asthma
Source: Medscape Allergy & Clinical Immunology Headlines [2016.08.25]
What benefit does biologic therapy offer patients with asthma? A new review examines the current role of these agents in managing this disease.
Current Opinion in Allergy and Clinical Immunology
Blood Eosinophil Markers to Predict Severity of Asthma
Source: Medscape Allergy & Clinical Immunology Headlines [2016.08.25]
Are measuring blood eosinophil levels an effective way to determine disease severity in asthma?
BMC Pulmonary Medicine
Late-onset asthma linked to increased heart disease, stroke risk
Source: Respiratory / Asthma News From Medical News Today [2016.08.25]
People who develop asthma as adults (late onset asthma) may also be at greater risk of developing heart disease and having a stroke, according to new research in Journal of the American Heart...
Published Studies Related to Aerobid (Flunisolide Inhalation)
Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...
High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.
Intranasal flunisolide treatment in children with adenoidal hypertrophy. [2007.10]
Adenoidal hypertrophy (AH) represents one of the most frequent indications for surgery in children and it has been proposed that treatment with intranasal corticosteroids can decrease the size of AH.In conclusion, this preliminary study demonstrates that an 8-week treatment with intranasal flunisolide is significantly associated with reduction of AH, thus preventing the recurrence to adenoidectomy, and is safe.
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...
Clinical Trials Related to Aerobid (Flunisolide Inhalation)
Flunisolide HFA in Children With Small Airway Disease [Not yet recruiting]
The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved
inhaled medication to treat asthma) affect the small airways in children with asthma.
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q
in adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking
beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.
Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and
out of the lungs). The large airways are located in the central lung. New research shows
that asthmatics also have inflammation in the small airways. The small airways are located
in the peripheral lung (the parts of the lung away from the central lung).
Until now, most of the inhaled medications available have been made up of big particles that
never reach the peripheral lung. The purpose of this study is to try to measure the level of
inflammation in the peripheral lung in asthmatics and see if this inflammation can be
decreased with different types of inhaled corticosteroids. The investigators will check
airway inflammation before and after use of an inhaled corticosteroid that has a large
particle size and should only reach the large airways (Flunisolide-CFC), and before and
after use of an inhaled, small particle corticosteroid that should reach both the large and
small airways (Flunisolide-HFA).
Subjects will make 6 study visits over two phases of the study. In the first phase, the
investigators will collect baseline information about subjects while they are using placebo
(inactive substance). In the second phase, subjects will take either the large or small
Visits will involve questionnaires and various tests measuring lung function (such as
spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be
measured as an indication of inflammation. Subjects will also measure and make note of lung
function at home twice daily using a peak expiratory flow meter. Two of the visits will
involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue
samples without surgery. Another two of the visits will involve the use of high resolution
computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy [Completed]
The objective of this study is to compare healthcare utilization and costs in
Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol
xinafoate combination or inhaled corticosteroids in a typical clinical practice using a
retrospective observational cohort study design of large managed care database. Outcomes on
interest include asthma related severe exacerbations defined as asthma related emergency
department visits, hospitalizations or combined emergency department/hospitalization. Other
outcomes of interest include use of albuterol, oral corticosteroids and overall asthma
related costs. Outcomes of interest will be compared between the two treatment cohorts
(fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids).
Dichotomous outcomes (emergency visits, hospitalizations etc) will be compared using Cox
regression hazards analysis assessing time to first event for each asthma related endpoint
adjusting for differences in baseline demographics such as age, gender, previous asthma
medication use, co morbidities, costs, and plan demographics. Total asthma related costs
will also be compared using generalized linear models adjusting for baseline differences.
Effect of Physiotherapy on Perceived Health Status in Hospitalized COPD Patients [Recruiting]
Chronic obstructive pulmonary disease (COPD) impacts negatively on the quality of life of
patients. Several studies have shown that acute exacerbations (AEs) decrease health-related
quality of life, pulmonary function and survival of COPD patients.
The objective of the present study is to examine the effects of a physical therapy program
on perceived health status in COPD patients hospitalized due to an acute exacerbation.